Research Article
Prevalence of Stroke in Individuals with Sickle Cell Disease Pre- and during Hydroxyurea Uses: A Descriptive Cross-Sectional Study in Tanzania
Table 2
Prevalence of stroke pre- and post-HU use among participants (n = 228).
| Variables | n (%) |
| Stroke status pre-hydroxyurea use | Yes | 28 (12.3) | No | 200 (87.7) | Stroke status post-hydroxyurea use | Yes | 6 (2.6) | No | 222 (97.4) | Range of hydroxyurea used per week in mg (minimum-maximum) 6000 (1000–7000) | | Dosage of HU used per week (mg) | <3500 | 59 (25.9) | 3500 | 132 (57.9) | >3500 | 37 (16.2) | Duration of HU use | < 2 years | 132 (57.9) | ≥ 2 years | 96 (42.1) |
|
|